SUBSCRIBE
SUBSCRIBE

Phase 3

Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
Lexicon Pharma Rockets on Late-Stage Diabetes Drug Data
September 9, 2016
 · 
2 min read
Juno Was Being Wooed to the Big Apple But Here's Why It's Staying in Seattle
Drug Development
Juno Surges as Small Cancer Study is Hailed a Success, Shows Promise for Other Drugs
September 8, 2016
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
September is a Busy Month for 7 Biotechs
September 2, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Why Cytokinetics Stock Dropped on the Good News of an Upcoming Phase III Trial
September 2, 2016
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
3 Biotechs Expecting to Release Clinical Trial Data Soon
September 1, 2016
 · 
3 min read
Genentech Grows on Promise of 70+ Drug Approvals
Drug Development
Genentech’s Tecentriq Shows Positive Data in Phase III Trial, Has an Upcoming Action Date in October
September 1, 2016
 · 
3 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Drug Development
Vertex Dumps Phase III Cystic Fibrosis Study
August 16, 2016
 · 
3 min read
As Biogen's Drug Shines, Eli Lilly Releases Detailed Results of Its Own Failure Solanezumab
Drug Development
Eli Lilly’s Breast Cancer Drug Failed to Meet Phase III Goals, But Panel Recommends Continuation of Trial
August 10, 2016
 · 
2 min read
Pharma Giant AstraZeneca PLC Scores Another FDA Breakthrough
Drug Development
AstraZeneca PLC’s Lung Cancer Drug Flunks Late-Stage Test
August 9, 2016
 · 
2 min read
3 Biotechs Breathing Down Bristol-Myers Squibb's Neck
Drug Development
Bristol-Myers Squibb’s Failed Lung Cancer Data Sends Stock Plunging
August 5, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
February 4, 2026
 · 
4 min read
Press Releases
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
 · 
9 min read
Press Releases
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 3, 2026
 · 
12 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
 · 
2 min read
Press Releases
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
 · 
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
 · 
8 min read
Press Releases
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 2, 2026
 · 
14 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
 · 
11 min read
Press Releases
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
February 1, 2026
 · 
12 min read
Press Releases
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 1, 2026
 · 
12 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 29, 2026
 · 
6 min read
Press Releases
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 29, 2026
 · 
4 min read
Press Releases
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 29, 2026
 · 
5 min read
Load More